TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34952736
Drug: Intravenous tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous tranexamic acid (TXA) 15 mg/kg
Study: 34487722
Drug: Start oral
Normalized name: Star Anise Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Start oral anticoagulation (101 participants)
Study: 34487722
Drug: Avoid oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avoid oral anticoagulation (102 participants)
Study: 32964986
Drug: VASPIN treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: VASPIN treatment
Study: 32964986
Drug: VASPIN treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: VASPIN treatment in HK-2 cells
Study: 36113532
Drug: One dose
Normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One dose of 2-valent vaccine (Cervarix)
Study: 36113532
Drug: One dose
Normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One dose of 9-valent vaccine (Gardasil 9)
Study: 34310978
Drug: TVB-2640 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: TVB-2640 25 mg
Study: 34310978
Drug: TVB-2640 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: TVB-2640 50 mg
Study: 34595801
Drug: Slow deep
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow deep breathing (SDB) intervention, 20-minute video 5 times weekly for 4 weeks
Study: 32720602
Drug: Simvastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (40 mg/day) + Ezetimibe (10 mg/day)
Study: 32720602
Drug: Simvastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (40 mg/day) monotherapy
Study: 32202256
Drug: Lopinavir/ritonavir combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lopinavir/ritonavir combination therapy for 14 days
Study: 33455765
Drug: Propylene glycol
Normalized name: Propylene Glycol
DrugBank: Propylene glycol (DB01839)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propylene glycol (PG) at 15.0 μL/g of dry matter (TRT)
Study: 33455765
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (0 μL/g of dry matter, CON)
Study: 32337700
Drug: Low-dose nalmefene
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose nalmefene (N1 group, n=40)
Study: 32337700
Drug: High-dose nalmefene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose nalmefene (N2 group, n=40)
Study: 32337700
Drug: Low-dose nalmefene
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose nalmefene (N1 group)
Study: 32337700
Drug: High-dose nalmefene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose nalmefene (N2 group)
Study: 32876468
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment (n=25)
Study: 36041396
Drug: 0.45 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.45 mg/kg selenium-enriched yeast (SeY)
Study: 34867233
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy for CP
Study: 35637515
Drug: Mindfulness-based stress
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-based stress reduction (MBSR) program for 2.5 hours weekly for 8 weeks
Study: 33434080
Drug: Fortified low-fat
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fortified low-fat yogurt (1500 IU nano encapsulated vitamin D3 per 150 g/d)
Study: 33434080
Drug: Fortified low-fat
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fortified low-fat milk (1500 IU nano encapsulated vitamin D3 per 200 g/d)
Study: 32167784
Drug: Direct Service
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct Service Model (6 sessions over 22 weeks of pharmacotherapy followed by behavior training)
Study: 35503446
Drug: Capsaicin (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsaicin (1.5 μg)
Study: 33882541
Drug: High Dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High Dose TXA (30 mg/kg loading dose followed by 10 mg/kg/h infusion)
Study: 33882541
Drug: Low Dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low Dose TXA (10 mg/kg loading dose followed by 1 mg/kg/h infusion)
Study: 33882541
Drug: High Dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High Dose TXA
Study: 33882541
Drug: Low Dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low Dose TXA
Study: 38670610
Drug: Intravenous immunoglobulins
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulins
Study: 36196609
Drug: BNT162b2 mRNA
Normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 Injectable Suspension [Comirnaty]
Approvals — FDA: no, EMA: no, PMDA: no
Description: BNT162b2 mRNA COVID-19 vaccine
Study: 32607749
Drug: Low-dose IL-2
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose IL-2 (0.125, 0.250, or 0.500 million international units (MIU)/m2, given daily for 5 days and then fortnightly for 1 year)
Study: 32607749
Drug: Low-dose IL-2
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose IL-2 (0.250 and 0.500 MIU m−2 day−1)
Study: 36350332
Drug: Gamified mobile
Normalized name: Chamaemelum nobile extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gamified mobile application for somatosensory training (daily use for 4 weeks)
Study: 33559636
Drug: Incisional Negative
Normalized name: GLYCERIN NEGATIVE CONTROL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Incisional Negative Pressure Wound Therapy (INPWT)
Study: 33414824
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (traditional rehabilitation therapy)
Study: 35222903
Drug: Nicotinamide 1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotinamide 1000 mg once daily for 12 weeks
Study: 35222903
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (antidiabetic therapy only)
Study: 35594970
Drug: Online cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Online cognitive behavior therapy (CBT) program with 8 modules and 8, 30-minute telephone sessions with a therapist (n = 45)
Study: 36171040
Drug: Integrated GP-paediatrician
Normalized name: carbetapentane citrate / guaifenesin Oral Solution [Pulmari-GP]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated GP-paediatrician model of care (weekly co-consultation sessions, monthly case discussions, phone and email support)
Study: 35073986
Drug: Resistant potato
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resistant potato starch (RPS), 15 g per day
Study: 35073986
Drug: Cornstarch (digestible
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cornstarch (digestible starch control), 15 g per day
Study: 34863332
Drug: Lenzilumab (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenzilumab (600 mg per dose, three doses delivered 8 hours apart)
Study: 36194764
Drug: NG/CT treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: NG/CT treatment records (n = 30,365)
Study: 36194764
Drug: Treatment records
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment records associated with gonorrhea and/or chlamydia (n = 67,895)
Study: 36194764
Drug: Testing episodes
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testing episodes not associated with treatment records (n = 122,694)
Study: 36194764
Drug: Same-day treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Same-day treatment for NG/CT testing episodes
Study: 32780636
Drug: Lidocaine injection
Normalized name: lidocaine Injection
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine injection (0.2% lidocaine in sterile water)
Study: 33780506
Drug: Simple information
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simple information treatment (explained that added sugars information was now available on the NF label)
Study: 33780506
Drug: Full information
Normalized name: Inflammation OTC Bruise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full information treatment (included additional details on interpreting added sugars content and associated diseases)
Study: 34043051
Drug: Foot massage
Normalized name: MENTHOL 13.5 mg in 1 mL TOPICAL LOTION [Foot Works Achy Foot Massager Pain Relieving]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Foot massage during chemotherapy (4 sessions, 7 min each foot, 40 min intervals)
Study: 32954737
Drug: Initial surgery
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial surgery followed by adjuvant chemotherapy
Study: 32954737
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy followed by cytoreductive surgery
Study: 33306556
Drug: Enhanced-prophylaxis (fluconazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced-prophylaxis (fluconazole 100 mg/day, azithromycin, isoniazid, cotrimoxazole)
Study: 34289879
Drug: Community-based health
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community-based health educational intervention administered by Female Community Health Volunteers (FCHVs)
Study: 32346711
Drug: Topical doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical doxycycline for 5 min before replantation
Study: 36361001
Drug: Task-oriented activities
Normalized name: Oriental melon
DrugBank: Muskmelon (DB15611)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Task-oriented activities of daily living (T-ADL) training
Study: 36082909
Drug: Enterally delivered
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enterally delivered glutamine (0.5 g/kg/day)
Study: 32048768
Drug: Each additional
Normalized name: chromous chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each additional cycle of treatment
Study: 35686212
Drug: Domiciliary nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domiciliary nasal high flow (NHF) therapy
Study: 34397699
Drug: Various treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various treatment regimens
Study: 33761873
Drug: Cadmium concentrations
Normalized name: cadmium
DrugBank: Cadmium (DB14085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cadmium concentrations (0, 15, 30, 45, and 60 mg L-1) for 60 days
Study: 34000676
Drug: License suspension
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: License suspension
Study: 36350591
Drug: Escitalopram (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram (10 to 20 mg, flexibly dosed) for 8 weeks
Study: 37813418
Drug: Early treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early treatment group
Study: 34779114
Drug: One-stage surgical
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-stage surgical protocol without ridge augmentation (Group A)
Study: 34779114
Drug: Two-stage surgical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-stage surgical protocol with ridge augmentation (Group B)
Study: 35843520
Drug: Tralokinumab (monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tralokinumab (monotherapy or in combination with topical corticosteroids)
Study: 35435639
Drug: Tramadol (100-300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol (100-300 mg/day)
Study: 35803302
Drug: Ventilatory strategy
Normalized name: VENTILATOR FILTER,THERMOFLO #6000S
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ventilatory strategy to prevent atelectasis (VESPA) with endotracheal intubation, recruitment maneuver, FiO2 titration (<100%), and PEEP of 8-10 cm H2O
Study: 34887855
Drug: Matrix M
Normalized name: Matrix metallopeptidase 9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matrix M adjuvanted H5N1 vaccine (30μg)
Study: 34887855
Drug: Matrix M
Normalized name: Matrix metallopeptidase 9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matrix M adjuvanted H5N1 vaccine (7.5μg)
Study: 34887855
Drug: Matrix M
Normalized name: Matrix metallopeptidase 9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matrix M adjuvanted H5N1 vaccine (1.5μg)
Study: 34887855
Drug: Non-adjuvanted H5N1
Normalized name: Influenza A monovalent (H5N1), ADJUVANTED-2013
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-adjuvanted H5N1 vaccine (30μg)
Study: 33930091
Drug: Medication reviews
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication reviews
Study: 34544393
Drug: e-health treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: e-health treatment for urinary incontinence
Study: 35442343
Drug: Terlipressin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terlipressin (1 mg IV bolus q 4 hourly for 2 days) in TG2 group
Study: 35442343
Drug: Terlipressin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terlipressin (1 mg IV bolus q 4 hourly for 5 days) in TG5 group
Study: 35442343
Drug: Control (0.9%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (0.9% normal saline, 10 mL IV bolus q 4 hourly) in TG0 group
Study: 33612059
Drug: Lenalidomide maintenance
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenalidomide maintenance (dose-escalated 2.5–10mg, 20/28 days per cycle for six months)
Study: 32430450
Drug: ETC120' (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: ETC120' (10 mg THC and 200 mg CBD)
Study: 35120753
Drug: Sustained-release pediatric
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release pediatric melatonin (PRM)
Study: 35395220
Drug: Ileal glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ileal glucose infusion (30g glucose and 3g 3-O-methylglucose)
Study: 35599504
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy plus proprioception training (PTR-PT)
Study: 35599504
Drug: Modified Constraint-Induced
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified Constraint-Induced Movement Therapy (PTR-mCIMT)
Study: 35599504
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (PTR)
Study: 34521084
Drug: Platelet nadir
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet nadir <100 × 10^3/?L
Study: 35705194
Drug: 9 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9 g/day perilla oil (HOI)
Study: 35705194
Drug: 3 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g/day perilla oil (LOI)
Study: 35899772
Drug: Early antiplatelet
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early antiplatelet treatment with 300 mg clopidogrel and 100 mg aspirin
Study: 32796301
Drug: Biosilicate conical
Normalized name: calcium aluminum borosilicate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biosilicate conical implants
Study: 36288885
Drug: Pentoxifylline (PTX)
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentoxifylline (PTX) full dose (400 mg TID)
Study: 36288885
Drug: Pentoxifylline (PTX)
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentoxifylline (PTX) reduced dose (200 mg TID)
Study: 36332503
Drug: Sub-dissociative dose
Normalized name: DAB(SUB 389)IL2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sub-dissociative dose ketamine (SDK)
Study: 33256540
Drug: Expressed self-contempt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Expressed self-contempt during brief psychiatric treatment
Study: 32048083
Drug: Tofacitinib continuous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofacitinib continuous treatment (10 mg twice daily)
Study: 32048083
Drug: Tofacitinib interrupted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofacitinib interrupted treatment (withdrawn for 2 weeks, then reinitiated)
Study: 35240317
Drug: NO3‐ supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: NO3‐ supplementation (140 ml of concentrated NO3‐ beetroot juice, 9.7 mmol, 0.6 gm NO3‐)
Study: 34077643
Drug: Nivolumab (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab (240 mg intravenously every 2 weeks for up to 1 year)
Study: 35213469
Drug: Intraoperative medications
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative medications prescribed based on pharmacogenomic results.
Study: 35213469
Drug: Total medications
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total medications prescribed considering pharmacogenomic results.
Study: 35213469
Drug: Genomically high-risk
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genomically high-risk medications administered.
Study: 35213469
Drug: Genomically cautionary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genomically cautionary medications administered.
Study: 36884054
Drug: Subcutaneous nitroglycerin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous nitroglycerin
Study: 34274016
Drug: Psychosocial Navigator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychosocial Navigator (PSN) intervention with monthly screening results and tailored recommendations for psychosocial distress and mental health symptoms.
Study: 36355991
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin type A (BoNT-A) treatment (10U-25U for temporalis muscle and 30U-75U for masseter muscle)
Study: 36355991
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin type A (BoNT-A) treatment
Study: 33165612
Drug: SPECTRUM investigational
Normalized name: Sentinel Spectrum
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPECTRUM investigational cigarettes (15.8 mg/g)
Study: 33165612
Drug: SPECTRUM investigational
Normalized name: Sentinel Spectrum
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPECTRUM investigational cigarettes (5.2 mg/g)
Study: 33165612
Drug: SPECTRUM investigational
Normalized name: Sentinel Spectrum
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPECTRUM investigational cigarettes (2.4 mg/g)
Study: 33165612
Drug: SPECTRUM investigational
Normalized name: Sentinel Spectrum
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPECTRUM investigational cigarettes (1.3 mg/g)
Study: 33165612
Drug: SPECTRUM investigational
Normalized name: Sentinel Spectrum
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPECTRUM investigational cigarettes (0.4 mg/g)
Study: 33055441
Drug: Oral intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral intake of ceramide-containing food (0.8 mg of dihydroceramide) for 12 weeks
Study: 34674222
Drug: Palbociclib 125
Normalized name: palbociclib 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palbociclib 125 mg once daily (q.d.)
Study: 34674222
Drug: Palbociclib 125
Normalized name: palbociclib 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palbociclib 125 mg q.d. plus erythromycin 500 mg three times daily for seven days
Study: 35428210
Drug: Hypofractionated treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypofractionated treatment arm (20 × 3 Gy)
Study: 35428210
Drug: Conventional fractionated
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional fractionated treatment arm (35 × 2 Gy)
Study: 35420334
Drug: Aspirin (placebo-controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (placebo-controlled trial)
Study: 34172436
Drug: efpeglenatide 6
Normalized name: Efpeglenatide
DrugBank: Efpeglenatide (DB15650)
Approvals — FDA: no, EMA: no, PMDA: no
Description: efpeglenatide 6 mg weekly (QW)
Study: 34172436
Drug: efpeglenatide 16
Normalized name: Efpeglenatide
DrugBank: Efpeglenatide (DB15650)
Approvals — FDA: no, EMA: no, PMDA: no
Description: efpeglenatide 16 mg monthly (QM)
Study: 34172436
Drug: efpeglenatide 6
Normalized name: Efpeglenatide
DrugBank: Efpeglenatide (DB15650)
Approvals — FDA: no, EMA: no, PMDA: no
Description: efpeglenatide 6 mg QW and 16 mg QM
Study: 34172436
Drug: liraglutide 1.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: liraglutide 1.8 mg daily (QD)
Study: 35226547
Drug: Intravenous Alteplase
Normalized name: Alteplase
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous Alteplase before Endovascular Thrombectomy
Study: 34992358
Drug: Nocturnal oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nocturnal oxygen therapy (NOT) at 3 L/min via nasal cannula
Study: 34992358
Drug: Placebo (ambient
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (ambient air) at 3 L/min via nasal cannula
Study: 35125385
Drug: Lidocaine (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (1.5 mg/kg bolus followed by 2 mg/kg/h infusion) + DEX (0.5 µg/kg)
Study: 35125385
Drug: Lidocaine (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (1.5 mg/kg bolus followed by 2 mg/kg/h infusion)
Study: 35125385
Drug: DEX (0.5
Normalized name: hydroxypropylbetadex (0.58-0.68 MS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DEX (0.5 µg/kg)
Study: 32739411
Drug: 1.8 g
Normalized name: Calciquid, 1.8 g/5 mL oral syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.8 g phlorizin-rich apple extract (HIGH)
Study: 32739411
Drug: 1.35 g
Normalized name: Octinoxate 1.35 g in 30 g TOPICAL CREAM [LBel Supremacie Teint]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.35 g phlorizin-rich apple extract (MED)
Study: 32739411
Drug: 0.9 g
Normalized name: Mannose 0.9 GM/1 DOSE Oral Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9 g phlorizin-rich apple extract (LOW)
Study: 32739411
Drug: 0 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 g phlorizin-rich apple extract (CON)
Study: 34171389
Drug: Intravenous iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous iron sucrose + oral iron bisglycinate (60 mg for 45 days)
Study: 34171389
Drug: Intravenous iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous iron sucrose only
Study: 34171389
Drug: Intravenous iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous iron sucrose + oral iron bisglycinate
Study: 35922216
Drug: Cinepazide maleate
Normalized name: cinepazide maleate
DrugBank: Cinepazide (DB12123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinepazide maleate injection
Study: 39474720
Drug: Esomeprazole 40
Normalized name: esomeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 40 mg/day